TY - JOUR
T1 - Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms
AU - Melquist, Stacey
AU - Craig, David W.
AU - Huentelman, Matthew J.
AU - Crook, Richard
AU - Pearson, John V.
AU - Baker, Matt
AU - Zismann, Victoria L.
AU - Gass, Jennifer
AU - Adamson, Jennifer
AU - Szelinger, Szabolcs
AU - Corneveaux, Jason
AU - Cannon, Ashley
AU - Coon, Keith D.
AU - Lincoln, Sarah
AU - Adler, Charles
AU - Tuite, Paul
AU - Calne, Donald B.
AU - Bigio, Eileen H.
AU - Uitti, Ryan J.
AU - Wszolek, Zbigniew K.
AU - Golbe, Lawrence I.
AU - Caselli, Richard J.
AU - Graff-Radford, Neill
AU - Litvan, Irene
AU - Farrer, Matthew J.
AU - Dickson, Dennis W.
AU - Hutton, Mike
AU - Stephan, Dietrich A.
N1 - Funding Information:
We are grateful to the patients and their families for their cooperation in this project. We also thank the Society for Progressive Supranuclear Palsy brain bank for providing samples. We thank John Gonzalez and Monica Castanedes-Casey in the Neuropathology Laboratory at Mayo Clinic Jacksonville for technical assistance. This research was funded by National Institutes of Aging grant PO1 AG 17216 (to M.H., D.W.D., and M.J.F.); the Mayo Foundation, USA; The Society for Progressive Supranuclear Palsy; and a Robert and Clarice Smith Fellowship. S.M. was funded by the National Research Service Award postdoctoral fellowship AG24030. Funding was also provided by a foundation grant from the Stardust Foundation (to D.W.C.) and the National Institutes of Health Neuroscience Blueprint grant 1U24NS043571 (to D.A.S.).
PY - 2007/4
Y1 - 2007/4
N2 - To date, only the H1 MAPT haplotype has been consistently associated with risk of developing the neurodegenerative disease progressive supranuclear palsy (PSP). We hypothesized that additional genetic loci maybe involved in conferring risk of PSP that could be identified through a pooling-based genomewide association study of >500,000 SNPs. Candidate SNPs with large differences in allelic frequency were identified by ranking all SNPs by their probe-intensity difference between cohorts. The MAPT H1 haplotype was strongly detected by this methodology, as was a second major locus on chromosome 11p12-p11 that showed evidence of association at allelic (P < .001), genotypic (P < .001), and haplotypic (P < .001) levels and was narrowed to a single haplotype block containing the DNA damage-binding protein 2 (DDB2) and lysosomal acid phosphatase 2 (ACP2) genes. Since DNA damage and lysosomal dysfunction have been implicated in aging and neurodegenerative processes, both genes are viable candidates for conferring risk of disease.
AB - To date, only the H1 MAPT haplotype has been consistently associated with risk of developing the neurodegenerative disease progressive supranuclear palsy (PSP). We hypothesized that additional genetic loci maybe involved in conferring risk of PSP that could be identified through a pooling-based genomewide association study of >500,000 SNPs. Candidate SNPs with large differences in allelic frequency were identified by ranking all SNPs by their probe-intensity difference between cohorts. The MAPT H1 haplotype was strongly detected by this methodology, as was a second major locus on chromosome 11p12-p11 that showed evidence of association at allelic (P < .001), genotypic (P < .001), and haplotypic (P < .001) levels and was narrowed to a single haplotype block containing the DNA damage-binding protein 2 (DDB2) and lysosomal acid phosphatase 2 (ACP2) genes. Since DNA damage and lysosomal dysfunction have been implicated in aging and neurodegenerative processes, both genes are viable candidates for conferring risk of disease.
UR - http://www.scopus.com/inward/record.url?scp=34147181052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34147181052&partnerID=8YFLogxK
U2 - 10.1086/513320
DO - 10.1086/513320
M3 - Article
C2 - 17357082
AN - SCOPUS:34147181052
SN - 0002-9297
VL - 80
SP - 769
EP - 778
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 4
ER -